The closing price of Globus Medical Inc (NYSE: GMED) was $51.98 for the day, up 0.64% from the previous closing price of $51.65. In other words, the price has increased by $+0.33 from its previous closing price. On the day, 970390 shares were traded.
Ratios:
Our analysis of GMED’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 42.59. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On October 20, 2023, ROTH MKM started tracking the stock assigning a Buy rating and target price of $75.
Stifel Upgraded its Hold to Buy on September 19, 2023, while the target price for the stock was maintained at $61.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 15 ’24 when Norwalk Leslie V sold 10,590 shares for $51.99 per share. The transaction valued at 550,574 led to the insider holds 17,419 shares of the business.
Huller Kelly sold 7,500 shares of GMED for $405,730 on Mar 01 ’24. The SVP, GC, Corporate Secretary now owns 0 shares after completing the transaction at $54.10 per share. On May 15 ’23, another insider, Lemaitre Dan, who serves as the Director of the company, sold 43,450 shares for $56.98 each. As a result, the insider received 2,475,977 and left with 10,800 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 6.99B and an Enterprise Value of 6.99B. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.63, and their Forward P/E ratio for the next fiscal year is 15.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.49 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at 4.46 whereas that against EBITDA is 20.18.
Stock Price History:
Over the past 52 weeks, GMED has reached a high of $62.88, while it has fallen to a 52-week low of $43.38. The 50-Day Moving Average of the stock is 54.06, while the 200-Day Moving Average is calculated to be 53.27.
Shares Statistics:
GMED traded an average of 1.19M shares per day over the past three months and 1.28M shares per day over the past ten days. A total of 113.91M shares are outstanding, with a floating share count of 112.00M. Insiders hold about 17.26% of the company’s shares, while institutions hold 80.19% stake in the company. Shares short for GMED as of Feb 29, 2024 were 5.73M with a Short Ratio of 4.80, compared to 5.32M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.24% and a Short% of Float of 5.12%.
Earnings Estimates
The firm’s stock currently is rated by 15 analysts. On average, analysts expect EPS of $0.57 for the current quarter, with a high estimate of $0.62 and a low estimate of $0.49, while EPS last year was $0.53. The consensus estimate for the next quarter is $0.66, with high estimates of $0.69 and low estimates of $0.63.
Analysts are recommending an EPS of between $2.72 and $2.68 for the fiscal current year, implying an average EPS of $2.69. EPS for the following year is $3.29, with 15 analysts recommending between $3.9 and $3.06.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $598.49M to a low estimate of $566.4M. As of the current estimate, Globus Medical Inc’s year-ago sales were $276.69M, an estimated increase of 111.90% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $616.39M, an increase of 111.40% less than the figure of $111.90% in the same quarter last year. There is a high estimate of $623M for the next quarter, whereas the lowest estimate is $606.4M.
A total of 15 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.48B, while the lowest revenue estimate was $2.44B, resulting in an average revenue estimate of $2.46B. In the same quarter a year ago, actual revenue was $1.57B, up 57.10% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $2.65B in the next fiscal year. The high estimate is $2.71B and the low estimate is $2.61B. The average revenue growth estimate for next year is up 7.60% from the average revenue estimate for this year.
